Health :: ORIDIS Biomed Licenses NIH’s Proprietary Tissue Micro-Array Technology

ORIDIS Biomed, a biopharmaceutical company announced that it has entered into a license agreement with the National Institutes of Health (NIH) for the worldwide commercial use of NIH’s proprietary Tissue Micro-Array (TMA) technology.

“We are pleased to have been granted by the NIH a license for this TMA technology,” said Georg Casari, PhD, Head of ORIDIS Biomed’s TISSOMICS(TM) business. “This license agreement further strengthens our TISSOMICS(TM) business for the life-science industry worldwide, where we offer our clients the ability to validate their research, such as biomarker and target verification programs.”

Tissue Micro-Arrays are a research tool, within ORIDIS Biomed’s TISSOMICS(TM) platform, that permits the rapid and simultaneous study of several hundred tissue samples, using standardized high-throughput analysis by in-house pathologists.


Leave a Comment